487 related articles for article (PubMed ID: 25025373)
1. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
Del Vecchio L; Locatelli F
Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
[TBL] [Abstract][Full Text] [Related]
2. New Treatment Approaches for the Anemia of CKD.
Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
[TBL] [Abstract][Full Text] [Related]
3. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
6. Anemia in chronic kidney disease.
Atkinson MA; Warady BA
Pediatr Nephrol; 2018 Feb; 33(2):227-238. PubMed ID: 28412770
[TBL] [Abstract][Full Text] [Related]
7. Therapy of anemia: is it only a number to reach or are there other variables to control?
Del Vecchio L; Locatelli F
Blood Purif; 2013; 36(1):37-40. PubMed ID: 23735594
[TBL] [Abstract][Full Text] [Related]
8. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M
Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465
[TBL] [Abstract][Full Text] [Related]
9. Anemia in conventional hemodialysis: Finding the optimal treatment balance.
Hasegawa T; Koiwa F; Akizawa T
Semin Dial; 2018 Nov; 31(6):599-606. PubMed ID: 29909605
[TBL] [Abstract][Full Text] [Related]
10. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
12. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639
[TBL] [Abstract][Full Text] [Related]
13. HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
Wyatt CM; Drüeke TB
Kidney Int; 2016 Nov; 90(5):923-925. PubMed ID: 27742192
[TBL] [Abstract][Full Text] [Related]
14. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
15. Chronic kidney disease-associated anemia: new remedies.
Del Vecchio L; Cavalli A; Tucci B; Locatelli F
Curr Opin Investig Drugs; 2010 Sep; 11(9):1030-8. PubMed ID: 20730698
[TBL] [Abstract][Full Text] [Related]
16. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
17. Current and future chemical therapies for treating anaemia in chronic kidney disease.
Locatelli F; Del Vecchio L; Luise MC
Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Therapy for Anemia in Renal Transplantation Patients by Prior Erythropoiesis Stimulating Agent Use.
Nakamura N; Aso S; Nakagawa C; Tachibana M; Fujikawa A; Tsubouchi K; Gunge N; Miyazaki T; Okabe Y; Matsuzaki H; Matsuoka H; Haga N
Transplant Proc; 2023 May; 55(4):829-831. PubMed ID: 37105829
[TBL] [Abstract][Full Text] [Related]
19. Renal anemia: current treatments and emerging molecules.
Heras-Benito M
Rev Clin Esp (Barc); 2023; 223(7):433-439. PubMed ID: 37348652
[TBL] [Abstract][Full Text] [Related]
20. Anemia management in chronic kidney disease and dialysis: a narrative review.
Collister D; Rigatto C; Tangri N
Curr Opin Nephrol Hypertens; 2017 May; 26(3):214-218. PubMed ID: 28306566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]